Table 1.

Characteristics of patients who experienced serious irAEs requiring treatment delay

RetreatmentDiscontinuationP
No. of patients; N (%)3830
Median age, years (range)64 (49–83)66 (42–84)0.59
Sex, female; N (%)18 (47)11 (37)0.46
Smoking history, N (%)0.51
 Yes33 (87)24 (80)
 No5 (13)6 (20)
Histology, N (%)0.06
 Adenocarcinoma23 (61)26 (87)
 Squamous11 (29)4 (13)
 LCNEC or NOS4 (10)0 (0)
Immunotherapy treatment data, N (%)0.18
 Anti–PD-1 or Anti–PD-L124 (63)24 (80)
 Combination w/anti–CTLA414 (37)6 (20)
Line of therapy, N (%)0.007
 First25 (66)9 (30)
 Second and beyond13 (34)21 (70)
Best overall response, N (%)0.62
 CR or PR18 (47)12 (40)
 SD or PD20 (53)18 (60)
  • Abbreviations: LCNEC, large-cell neuroendocrine cancer; NOS, not otherwise specified carcinoma; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; CTLA-4, cytotoxic T-lymphocyte–associated antigen 4; CR, complete response; SD, stable disease; PD, progressive disease.